We are live on ! Find out more

Celldex Therapeutics

CLDX

Market cap $2.32B

29.50 USD

+0.25

0.85%

At close Updated Oct 26, 4:00 PM EDT

Pre-market

After hours

29.50

0.00

0%

1 day

0.85%

5 days

-1.63%

1 month

-6.32%

3 months

-17.25%

6 months

-12.36%

Year to date

9.22%

1 year

7.78%

5 years

-35.62%

10 years

-39.11%

About: Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.

Employees: 198

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 20%

Neutral 70%

Negative 10%

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX)

NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Celldex Therapeutics, Inc. (NASDAQ: CLDX) on behalf of the company's shareholders. The investigation seeks to determine whether Celldex Therapeutics's directors breached their fiduciary duties in connection with recent corporate actions.

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX)

Celldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous Urticaria Transcript

Celldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous Urticaria Transcript

Celldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous Urticaria Transcript

Celldex Prepares For 2027 FDA Submission for Chronic Skin Disease

Celldex Therapeutics Inc. (NASDAQ:CLDX) on Tuesday shared topline results from its Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 clinical trials. The studies evaluate barzolvolimab for patients with chronic spontaneous urticaria (CSU) who experience inadequate symptom control using H1-antihistamines, including those who are advanced therapy experienced or refractory.

Celldex Prepares For 2027 FDA Submission for Chronic Skin Disease

Celldex Phase III CSU Trials Hit Endpoints as Barzolvolimab Shows Durable Responses

Celldex Therapeutics NASDAQ: CLDX reported positive top-line results from its two Phase III EMBARQ-CSU studies of barzolvolimab in adults with chronic spontaneous urticaria, or CSU, who remained symptomatic despite H1 antihistamine treatment. The company said both evaluated dose regimens met the primary endpoint and all key secondary endpoints, with efficacy sustained or deepening through 24 weeks.

Celldex Phase III CSU Trials Hit Endpoints as Barzolvolimab Shows Durable Responses

Zacks Investment Research

4 Biotech Stocks With Key Clinical Readouts Expected This Fall

KOD, CLDX, RAPP and PCVX face key clinical readouts this fall that could influence their drug and vaccine pipelines.

4 Biotech Stocks With Key Clinical Readouts Expected This Fall

Celldex's skin disease drug meets goals in two late-stage trials

Celldex Therapeutics said on Tuesday its experimental drug for a skin disease met the main and secondary goals of two late-stage trials.

Celldex's skin disease drug meets goals in two late-stage trials

Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints

Best-in-disease results showed rapid, profound, sustained efficacy, supporting barzolvolimab's potential to be a transformational therapy in CSU EMBARQ-CSU1 and -CSU2 met primary and all key secondary endpoints at 12 weeks across both studies and both dose groups Clinically meaningful and statistically significant benefit demonstrated in omalizumab refractory CSU and patients with severe disease or severe angioedema Efficacy sustained or deepened from weeks 12 to 24 Well tolerated with a favorable safety profile through 24 weeks; consistent with prior studies Treatment will continue in both trials to 52 weeks; BLA submission anticipated in 2027 Company to host webcast today at 8:00 am ET HAMPTON, N.J., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported positive topline results from the Company's Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials evaluating two doses of barzolvolimab in patients with chronic spontaneous urticaria (CSU) whose symptoms are inadequately controlled by H1-antihistamines.

Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints

Celldex to Present at Upcoming Investor Conference

HAMPTON, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the upcoming Cantor Global Healthcare Conference on September 10, 2026 at 8:00am ET.

Celldex to Present at Upcoming Investor Conference

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX)

NEW YORK, Aug. 24, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Celldex Therapeutics, Inc. (NASDAQ: CLDX) on behalf of the company's shareholders. The investigation seeks to determine whether Celldex Therapeutics's directors breached their fiduciary duties in connection with recent corporate actions.

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX)

Zacks Investment Research

Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates

Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.94 per share versus the Zacks Consensus Estimate of a loss of $1.04. This compares to a loss of $0.85 per share a year ago.

Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates

See News Rankings

Price charts implemented using Lightweight Charts™